Drugs /
infliximab
Back to Drugs List
Overview
Trade Name(s):
Remicade
NCI Definition [1]:
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
Clinical Trials
Infliximab has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating infliximab, 1 is phase 1 (1 open).
Melanoma is the most common disease being investigated in infliximab clinical trials [2].
Drug Details
Synonyms [2]:
Remicade, antibody ca2, monoclonal, mab ca2, infliximab, inf, infliximab (product), ig gamma-1 chain c region, infliximab, infliximab [chemical/ingredient], infliximab (substance), monoclonal antibody ca2, inflix, ca2, ca2, monoclonal antibody, infliximab, avakine
Drug Target(s) [2]:
TNF
NCIT ID [1]:
C1789
SNOMED ID [1]:
F-61AF7
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
